Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (Annals of Hematology, (2021), 100, 5, (1181-1194), 10.1007/s00277-021-04465-4)